K

    Korro Bio, Inc. (KRRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.49
    -0.42 (-3.25%)

    Market Cap: $183.92M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(18/28)
    Avg Surprise
    -74.69%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.25
    Range$-2.04 - $-0.93
    10 analysts
    EPS Revisions
    3
    0
    7d
    3
    0
    30d
    EPS Estimate Drift
    90d ago$-1.20+3.7%
    60d ago$-1.27-1.7%
    30d ago$-1.27-1.7%
    7d ago$-1.25+0.0%
    Current$-1.25
    Revenue Consensus
    $166670
    Range$0 - $2M
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.67
    Range$-2.74 - $0.29
    10 analysts
    Revenue Consensus
    $-438150
    Range$-771480 - $2M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.67---
    Sep 26EST
    		-$-1.25---
    Jun 26
    Reported Aug 6
    		$-1.07$-1.54+30.52%Beat+60.9%
    Mar 26
    Reported May 7
    		$-1.69$-1.98+14.73%Beat+32.1%
    Dec 25
    Reported Mar 12
    		$-1.65$-2.14+22.90%Beat+27.0%
    Sep 25
    Reported Nov 12
    		$-1.92$-2.68+28.36%Beat+15.0%
    Jun 25
    Reported Aug 12
    		$-2.74$-2.59-5.79%Miss-12.8%
    Mar 25
    Reported May 7
    		$-2.49$-2.62+4.96%Beat-2.0%
    Dec 24
    Reported Mar 18
    		$-2.26$-2.51+10.06%Beat+91.2%
    Sep 24
    Reported Nov 12
    		$-2.26$-2.53+10.67%Beat+85.4%
    Jun 24
    Reported Aug 13
    		$-2.43$-2.43+0.00%Beat-710.0%
    Mar 24
    Reported May 14
    		$-2.44$-2.49+2.01%Beat-343.6%
    Dec 23
    Reported Mar 29
    		$-25.65$-2.36-986.86%Miss-5134.7%
    Sep 23
    Reported Nov 2
    		$-15.50$-17.73+12.58%Beat-2718.2%
    Jun 23
    Reported Aug 10
    		$-0.30$-0.36+16.67%Beat+50.8%
    Mar 23
    Reported May 12
    		$-0.55$-0.42-30.95%Miss+17.9%
    Dec 22
    Reported Mar 10
    		$-0.49$-0.63+22.35%Beat+21.0%
    Sep 22
    Reported Dec 29
    		$-0.55$-0.57+3.51%Beat+24.7%
    Jun 22
    Reported Sep 28
    		$-0.61$-0.66+8.04%Beat-17.3%
    Mar 22
    Reported Jun 29
    		$-0.67$-0.64-5.36%Miss-11.7%
    Dec 21
    Reported Mar 30
    		$-0.62$0.15-506.02%Miss-106.7%
    Sep 21
    Reported Dec 29
    		$-0.73$-0.59-23.94%Miss-356.2%
    Jun 21
    Reported Sep 28
    		$-0.52$-0.51-2.24%Miss-173.7%
    Mar 21
    Reported Jun 28
    		$-0.60$0.14-536.36%Miss-275.0%
    Dec 20
    Reported Mar 30
    		$-0.30$-0.25-18.11%Miss-57.9%
    Sep 20
    Reported Nov 16
    		$-0.16$-0.28+42.34%Beat+78.1%
    Jun 20
    Reported Aug 12
    		$-0.19$-0.19+0.00%Beat+32.1%
    Mar 20
    Reported Jun 29
    		$-0.16$-0.17+5.88%Beat-
    Dec 19
    Reported Mar 30
    		$-0.19$0.10-290.00%Miss-
    Sep 19
    Reported Nov 18
    		$-0.73N/A+78.66%Beat-
    Jun 19
    Reported Sep 23
    		$-0.28$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.97EV/EBITDA-5.60x
    Price/FCF-3.22xFCF Yield-31.02%
    Profitability
    Profit Margin0.00%Operating Margin-3228.00%
    ROE-97.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio9.55xQuick Ratio9.55x
    Trading Statistics
    Beta2.21Avg Volume88.87K
    52-Week High$55.8952-Week Low$5.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.24
    SMA 20$13.03
    SMA 50$12.75
    SMA 200$11.25
    EMA 10$13.08
    EMA 20$12.92
    EMA 50$12.62
    EMA 200$13.92

    MACD

    Line: 0.23Signal: 0.29Hist: -0.06

    ADX

    ADX: 19.3+DI: 21.7-DI: 22.7

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down16.0
    PSAR$13.88

    Bollinger Bands

    Upper Band$14.39
    Lower Band$11.67
    %B Position2085%(Upper)
    Band Width0.30

    RSI (14-Day)

    Neutral
    46.6

    Momentum Oscillators

    Stoch %K23.2
    Stoch %D44.5
    Williams %R-89.0
    ROC (10d)-4.9%
    Momentum-0.65
    CCI (20d)-53.2
    MFI (14d)48.4

    Volatility Measures

    ATR (14d)$0.82(6.5%)
    StdDev (20d)0.68
    Hist Vol60.9%(High)

    Volume Flow

    VWAP$12.60
    OBV-444.5K
    AD Line-3.9M
    CMF (20d)0.159

    Volume Metrics

    Avg Vol (20d)88.6K
    Vol Ratio1.0x
    VWMA (20d)$12.93

    Pivot Points

    R3$14.12
    R2$13.84
    R1$13.37
    Pivot Point$13.09
    S1$12.62
    S2$12.34
    S3$11.87

    Advanced Oscillators

    TSI9.25
    Ultimate Osc44.9
    KST101.15

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$1.29M$1.09M$1.46M$2.55M$2.27M$0$0$0$0$0
    Cost of Revenue$0$0$649,000$0$0$0$-1,447,000$0$0$0$1.75M$0
    Gross Profit$0$0$1.29M$1.09M$1.46M$2.55M$2.27M$0$0$0$-1,751,000$0
    Operating Expenses$20.11M$20.44M$51.69M$20.33M$28.66M$27.57M$25.31M$23.29M$24.13M$21.45M$26.89M$19.15M
    R&D$13.59M$12.95M$10.98M$13.82M$20.14M$19.74M$16.96M$15.96M$17.14M$13.57M$15.42M$14.01M
    SG&A$6.52M$7.49M$6.19M$6.51M$7.29M$7.83M$8.35M$7.33M$6.99M$7.88M$11.47M$5.14M
    Operating Income$-20,110,000$-20,436,000$-50,396,000$-19,237,000$-27,202,000$-25,020,000$-23,040,000$-23,292,000$-24,125,000$-21,453,000$-26,892,000$-19,148,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-18,808,000$-19,530,000$-49,406,000$-18,061,000$-25,769,000$-23,387,000$-21,096,000$-21,008,000$-21,796,000$-19,540,000$-25,426,000$-18,492,000
    Income Tax Expense$108,000$95,000$636,000$0$1,000$0$103,000$-9,000$30,000$17,000$0$0
    Net Income$-18,916,000$-19,625,000$-50,042,000$-18,061,000$-25,770,000$-23,387,000$-21,199,000$-20,999,000$-21,826,000$-19,557,000$-25,426,000$-18,492,000
    EBITDA$-18,442,000$-19,148,000$-48,779,000$-16,929,000$-24,622,000$-22,502,000$-20,466,000$-21,131,000$-21,246,000$-18,814,000$-24,441,000$-17,574,000
    EBIT$-18,808,000$-19,530,000$-49,406,000$-18,061,000$-25,769,000$-23,387,000$-21,096,000$-21,008,000$-21,796,000$-19,540,000$-25,426,000$-18,492,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KRRO

    News

    Korro to Participate in Upcoming Investor Conferences

    Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company focused on genetic medicines, announced that its President & Chief Executive Officer, Ram Aiyar, will participate in upcoming investor conferences. The company leverages its OPERA® platform to develop treatments for rare and prevalent diseases. This announcement was distributed via GlobeNewswire.

    Barchart.com•8/27/26•
    Somewhat-Bullish

    Korro to Participate in Upcoming Investor Conferences

    Korro Bio, Inc. (Nasdaq: KRRO) announced that its President & CEO, Ram Aiyar, will participate in two upcoming investor conferences. These include the Citi 2026 Biopharma Back to School Summit on September 9th, 2026, and the 2026 Cantor Global Healthcare Conference on September 10th, 2026. Korro will leverage these events to discuss its novel oligonucleotide promoted editing of RNA (OPERA®) platform for genetic medicines.

    The Manila Times•8/27/26•
    Somewhat-Bullish

    Korro Bio (KRRO) director-tied funds sell 28K shares on Aug. 19

    Korro Bio (KRRO) director Jean Francois Formela's associated venture funds, Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., sold a total of 28,468 shares of common stock on August 19, 2026. The sales were executed at a weighted average price of $14.00 per share under a Rule 10b5-1 trading plan. Formela disclaims beneficial ownership except for any pecuniary interest in these indirect holdings.

    Stock Titan•8/21/26•
    Bearish

    Form 8K Korro Bio Inc For: 19 August By Investing.com

    This article reports that Korro Bio Inc. filed a Form 8K on August 19, 2026. The filing is brief and does not contain additional details within the provided content. The stock symbol KRRO is noted as having increased by 3.43%.

    Investing.com Nigeria•8/20/26•
    Neutral

    Korro Bio (KRRO) fund eyes new sale after $1.45M June trade

    Atlas-affiliated funds have filed a Form 144 to sell 23,584 shares of Korro Bio (KRRO) common stock, valued at $311,780.48. This filing follows several significant sales by Atlas Venture Fund XI and Atlas Venture Opportunity Fund II in the past three months, including a June sale of over 100,000 shares for $1.45 million. The document provides details on proposed and prior sales, outstanding shares, and definitions of relevant SEC regulations.

    Stock Titan•8/20/26•
    Neutral

    Frequently Asked Questions About KRRO

    Does KRRO pay dividends?
    Korro Bio, Inc. (KRRO) does not currently pay a regular dividend.
    What is KRRO's market cap?
    Korro Bio, Inc. (KRRO) has a market capitalization of $183.92M with a current stock price of $12.49.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In